MONTREAL, May 29, 2013 /CNW/ - NEOMED and AstraZeneca announced today
the expansion of their strategic partnership, further enabling NEOMED's
mission of delivering novel therapeutic solutions for unmet medical
needs. AstraZeneca will provide NEOMED access to up to 250,000
high-quality compounds from its small molecule compound library to be
used to identify candidate compounds for selected targets. The goal is
to identify compounds that could potentially become new medicines for a
broad range of diseases.
Under the terms of the agreement, NEOMED will work with academic
researchers and AstraZeneca scientists to identify active compounds and
progress them into pharmaceutical lead candidates to achieve in vivo proof-of-concept, one of the key steps in developing new medicines.
Using High Throughput Screening, initial chemical starting points (hits) for innovative targets
emerging from academic research will be identified from this compound
collection. This step will be performed by NEOMED's network of partners
"This exceptional collection of high-quality compounds will be very
useful to identify early chemical starting points for novel targets
identified by academic institutions," said Philippe Walker, Chief
Scientific Officer of NEOMED. "This new collaboration is fully aligned
with our key objectives to stimulate translational research and deliver
innovative therapeutics for unmet medical needs."
"We are very pleased to expand our relationship with AstraZeneca with
this collaboration. We hope that this initiative will be followed by
other pharmaceutical companies as an example of how a public-private
alliance can transform the way in which they identify new medicines,"
said Max Fehlmann, President and Chief Executive Officer of NEOMED and
the NEOMED Institute.
"Linking industry and academia can help advance the discovery of
potential new medicines in a broad range of disease areas for patients
who desperately need them," said Peter Simpson, Director of Screening
Sciences at AstraZeneca. "This collaboration with NEOMED is part of
AstraZeneca's efforts to share our compound libraries and to support
the generation of quality lead series for important and novel drug
"Today's research announcement is another important milestone in the
relationship between AstraZeneca Canada, the NEOMED Institute, and the
Canadian scientific community," said Elaine Campbell, President of
AstraZeneca Canada Inc. "We're proud to be announcing another unique
Canadian collaboration in health sciences research, one which will
advance drug discovery and support biopharmaceutical advances that
improve the health of patients across a number of important disease
About NEOMED and the NEOMED Institute
NEOMED is a not-for-profit, public-private Pharma alliance dedicated to
drug discovery and development, acting as a foster home for promising
assets emerging from academia and biotechnology companies. NEOMED
provides industry-level expertise and funding to bring emerging
therapeutic approaches up to human proof-of-concept, a stage where the
projects will become attractive to the biopharmaceutical industry.
NEOMED is funded jointly by AstraZeneca, Pfizer and the Ministère des
finances et de l'Économie du Québec.
NEOMED is established within the NEOMED Institute, a state-of-the-art
R&D facility in the Montreal Technoparc. The Institute acts as an
open-access drug discovery hub hosting commercial groups and providing
a unique environment to foster innovation, collaboration and
For more information, please visit: www.neomed.ca
AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialization of
prescription medicines, primarily for the treatment of cardiovascular,
metabolic, respiratory, inflammation, autoimmune, oncology, infection
and neuroscience diseases. AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients
worldwide. For more information please visit: www.astrazeneca.com
AstraZeneca Canada recently announced the donation of $35 million to the
NEOMED Institute. This donation includes land, a state-of-the-art
research facility, and leading-edge laboratory equipment. It also
includes the donation of intellectual property to three AstraZeneca
pain molecules and projects, as well as $5 million to support the
activities of the Institute. AstraZeneca's Canadian headquarters are
located in Mississauga, Ontario.
SOURCE: AstraZeneca Canada Inc.
For further information:
Mounia Azzi, PhD
Director, Scientific Affairs
Director, Corporate Communications
AstraZeneca Canada Inc.